CLLS — Cellectis S.A.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: FR
• Exchange: NASDAQ
• Employees: 216
• Website: https://www.cellectis.com

Latest SEC filings for CLLS

• 6-K — 2026-09-14
• 6-K/A — 2026-09-11
• 6-K — 2026-09-01
• S-8 — 2026-08-06
• 6-K — 2026-08-06
• 6-K — 2026-07-30
• 6-K — 2026-06-25
• 6-K — 2026-06-25
• 6-K — 2026-06-11
• 6-K — 2026-06-09

Latest CLLS news

• 2026-10-15 — Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm (GlobeNewswire Inc.)
• 2026-10-14 — Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz (GlobeNewswire Inc.)
• 2026-10-13 — INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS (globenewswire.com)
• 2026-10-08 — INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS (prnewswire.com)
• 2026-10-06 — INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS (globenewswire.com)
• 2026-10-01 — Cellectis Unveils In Vivo Gene-Editing Plans for Severe Lipid Disorders (marketbeat.com)
• 2026-10-01 — INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS (prnewswire.com)
• 2026-09-29 — INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS (globenewswire.com)

Abrir análisis completo

Educational tool only — not investment advice.